Navigation Links
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Date:10/22/2007

ombining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
2. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
3. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
4. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
5. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007
7. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
8. Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR
9. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
10. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
11. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ... Pharmaceutical Industries Ltd (NYSE: TEVA ) and ...
(Date:1/15/2014)... -- Tegra Medical is very pleased to announce the ... its new Chief Executive Officer.  Mark was promoted from ... he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in ... and manufacturing experience in medical device businesses, both in ...
(Date:1/15/2014)... 2014 The Cadence Fitness & Health ... Center by the Medical Fitness Association, a non-profit ... to achieve their full potential. The Cadence Fitness ... center in the western suburbs and second in ... the Cadence Fitness & Health Center meets guidelines ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... Cochlear, the global leader in implantable hearing ... Clark Cochlear Scholarship. Presented by Cochlear Americas, the Graeme ... seniors who,ve demonstrated exceptional achievements both in the classroom ... implant and will receive financial assistance toward their chosen ...
... PHILADELPHIA , May 4 ... SHPGY ), the global specialty biopharmaceutical company, today announced ... a change to the prescribing information for its once-daily ... ® (lisdexamfetamine dimesylate) Capsules CII, to include supplemental ...
Cached Medicine Technology:Cochlear Americas Honors Achievements of Cochlear Implant Recipients during May's Better Hearing & Speech Month 2Cochlear Americas Honors Achievements of Cochlear Implant Recipients during May's Better Hearing & Speech Month 3Cochlear Americas Honors Achievements of Cochlear Implant Recipients during May's Better Hearing & Speech Month 4FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 2FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 3FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 4FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 5FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 6FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 7FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 8
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... patients is in early period , , TUESDAY, Feb. 5 (HealthDay ... after heart patients stop taking the clot-preventing drug Plavix are ... make this observation," said Dr. P. Michael Ho, a cardiologist ... a report in the Feb. 6 issue of the ...
... ,PLAY SAFE IN THE SUN, ... ... a,subsidiary of the L,Oreal Group, announced that they have granted the,Women,s Dermatologic ... Safe in the Sun campaign, effective April,2008. The WDS educational outreach campaign ...
... William F. Balistreri, MD, Editor of The Journal of ... the Study of Liver Diseases (AASLD) 2007 Distinguished Service ... AASLD as well as to the liver disease community. ... award. , The AASLD was privileged to honor Dr. ...
... of the sardine fishery off California for decades has ... large fluctuations in the sardine population. Before its collapse, ... and formed the setting of John Steinbecks Cannery Row ... Oceanography at UC San Diego have now shed light ...
... Magazine,s list ranks 33, COLUMBUS, Ga., Feb. ... education and leadership programs helped Aflac leap to,Number ... for,employees according to Training Magazine,s annual Top 125 ... Georgia World Congress Center, the,insurer was honored for ...
... NewYork-Presbyterian Hospital/Weill Cornell Medical Center has created an ... and treatment of the disease. The new Cancer ... Andrew Dannenberg. , A joint initiative of Weill ... will create strengthened and expanded research programs and ...
Cached Medicine News:Health News:First 90 Days After Stopping Plavix Most Dangerous 2Health News:L'Oreal USA Announces Three-Year Support of Women's Dermatologic Society Foundation Community Outreach 2Health News:L'Oreal USA Announces Three-Year Support of Women's Dermatologic Society Foundation Community Outreach 3Health News:William F. Balistreri, M.D., honored with Distinguished Service Award by AASLD 2Health News:Scripps scientists peg wind as the force behind fish booms and busts 2Health News:Scripps scientists peg wind as the force behind fish booms and busts 3Health News:Training Magazine Applauds Aflac's Employee Learning Programs 2Health News:Training Magazine Applauds Aflac's Employee Learning Programs 3Health News:NewYork-Presbyterian/Weill Cornell creates world-class cancer center 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: